New appointment at Trubion
This article was originally published in Scrip
Trubion Pharmaceuticals, a US biopharmaceutical company creating a pipeline of protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer, has named Dr Scott Stromatt senior vice-president and chief medical officer. He succeeds Dr Daniel Burge, who will be resigning his position with the company later this month. Dr Stromatt was most recently executive vice-president of clinical and regulatory affairs at Cell Therapeutics.